Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Degarelix Efficacy and Safety in Taiwanese Prostate Cancer Patients
NCT01220869Phase 3Completed
- Sponsor
- Ferring Pharmaceuticals
- Start
- Dec 2010
- Primary completion
- Oct 2012
- Modality
- Peptides, Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of degarelix in prostate cancer (PCa), sponsored by Ferring Pharmaceuticals. Started Dec 2010; status: completed.
02
Drugs
degarelix
03
Conditions
prostate cancer (PCa)
Beyond the preview
Go deeper on NCT01220869.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01220869.